In contrast to cancers with APC or other defects in the β-catenin destruction complex, colorectal cancers with RNF43 mutations may retain WNT pathway ligands dependence and may as a result be better targets for porcupine and tankyrase inhibitors [45]. Here, RNF43 is linked to colorectal cancer.